Lori A. Leslie, MD, an expert on CLL, talks about factors that influence treatment decisions. Lori A. Leslie, MD: Let’s talk about the types of patient factors we think about when selecting a ...

First-line ibrutinib (Imbruvica) plus venetoclax (Venclexta) led to high response and survival rates in patients with chronic lymphocytic leukemia (CLL) whether or not their cancer harbored high-risk ...

DEAR MAYO CLINIC: I was recently diagnosed with chronic lymphocytic leukemia. I am 55 years old, exercise regularly and feel fine. I have no symptoms. My doctor’s approach is to "watch and wait." I’m ...

Which Is the Best Tyrosine Kinase Inhibitor for Newly Diagnosed Chronic Myelogenous Leukemia? Chronic lymphocytic leukemia (CLL) remains an incurable disease, except in rare cases treated with ...

MIAMI, FLORIDA (EMBARGOED UNTIL FEB. 1, 2024, AT 2 P.M. ET) – New research from Sylvester Comprehensive Cancer Center at the University of Miami Miller School of Medicine and collaborating ...

Lori A. Leslie, MD, and Hoshiyuki Iida, APN, provide an overview of chronic lymphocytic leukemia and the risk stratification process. Lori A. Leslie, MD: Hello, and welcome to CURE Expert Connections® ...

Chronic lymphocytic leukemia (CLL) and prolymphocytic leukemia (PLL) are types of blood cancer. They develop in types of white blood cells called B cells or T cells, or the precursors to these cells.

Improvements seen in overall survival, progression-free survival, and cancer-specific survival. HealthDay News — For patients with chronic lymphocytic leukemia (CLL) and small lymphocytic leukemia ...

Combination therapy has potential to be an all-oral, fixed-duration regimen for previously untreated patients with CLL Application is supported by data from the Phase 3 AMPLIFY trial that showed ...

Experts recently set out to determine whether distinct subpopulations of clonal cells with different proliferative potential exist within the same individual with CLL. The study used deuterium-labeled ...